Welcome to our dedicated page for IB Acquisition SEC filings (Ticker: IBAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IB Acquisition Corp. filings document the formal disclosure record of a SPAC, including trust-account amendments, deadline-extension mechanics, shareholder votes, material definitive agreements and capital-structure terms. The company’s reports describe common stock and rights listed on Nasdaq, with each right entitling the holder to receive one-twentieth of one share upon consummation of an initial business combination.
Its SEC record includes Form 8-K material-event reports and proxy materials covering special-meeting proposals, amendments to the Investment Management Trust Agreement, articles-of-incorporation changes, redemption and liquidation provisions, governance matters and business-combination related agreements.
IB Acquisition Corp. reported that GNQ Insilico Inc. entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company on March 13, 2026 to collaborate on sales, marketing, development and alliance activities advancing AI-driven drug discovery and precision medicine solutions.
The collaboration has a global territory, an initial term of two years and is non-exclusive. The parties will jointly market combined solutions that integrate GNQ’s AI platforms with the Strategic Partner’s consulting, cloud, and quantum computing capabilities. This Form 8-K also states that IB Acquisition intends to file a Form S-4 registration statement and a proxy statement/prospectus in connection with the proposed business combination with GNQ.
IB Acquisition Corp. reports that its prospective merger partner, GNQ Insilico Inc., has entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company. The two-year, non-exclusive collaboration will jointly market AI-driven drug discovery and precision medicine solutions worldwide, combining GNQ’s proprietary AI platforms with the partner’s consulting, cloud, and quantum computing capabilities.
The report also reiterates a proposed business combination between IB Acquisition and GNQ. IB Acquisition plans to file a Form S-4 registration statement with the SEC, including a joint proxy statement/prospectus that will be sent to its stockholders in connection with the transaction.
IB Acquisition Corp. entered into a Business Combination Agreement to acquire GNQ Insilico Inc. by way of a statutory plan of arrangement under Canadian law. The Arrangement Consideration is stated as $500,000,000 plus any Revenue or Share Price Earnouts, with exchange mechanics tying issuance to a Company Exchange Ratio.
The transaction is subject to customary closing conditions including SPAC stockholder approval, court orders in Ontario, regulatory approvals, effectiveness of a Form S-4 registration statement, Nasdaq/NYSE listing approval, minimum net tangible assets of $5,000,001 at closing after redemptions and a possible PIPE, and other conditions. A $10,000,000 break-up fee applies for certain fraudulent or willful breaches. A concurrent Bridge Financing of up to $2,000,000 was arranged, with an initial $250,000 secured convertible note and five-year warrants.
IB Acquisition Corp. has entered a definitive business combination agreement to acquire GNQ Insilico Inc., valuing GNQ at US$500,000,000 plus potential revenue and share price earnouts. GNQ will become a Nasdaq-listed AI- and quantum-driven drug development company following a plan of arrangement under Canadian law.
The transaction is expected to provide approximately US$15 million of proceeds to GNQ through cash in IB Acquisition’s trust account and a PIPE of up to US$10 million, alongside a separate bridge financing of up to US$2,000,000 in 10% secured convertible notes and warrants. Closing, targeted for the third quarter of 2026, is subject to shareholder approvals, court orders, regulatory clearances, a minimum of US$5,000,001 in IB Acquisition net tangible assets, and at least US$15.0 million of available cash.
IB Acquisition Corp. is asking stockholders to approve a six-month extension of the deadline to complete its initial business combination, pushing the cutoff to September 28, 2026. This requires support from at least 65% of all outstanding common shares.
Holders of public shares can redeem for cash in connection with the extension, at an amount based on the cash in the trust account, which was about $16.1 million as of the record date. The company estimates this would be roughly $10.76 per public share. If the extension fails, the SPAC expects to liquidate and return trust cash to public holders.
Stockholders will also vote on amending the trust agreement to align it with the new deadline, plus an adjournment proposal that would let the board postpone the meeting if turnout or support is insufficient. As of the February 11, 2026 record date, there were 5,739,970 common shares outstanding, and insiders and affiliates controlled about 63% of the vote.
IB Acquisition Corp. is asking stockholders to approve a six‑month extension of its deadline to complete an initial business combination from March 28, 2026 to September 28, 2026. This requires approval of an Extension Proposal, a related Trust Amendment, and an Adjournment Proposal.
The proxy explains that if the extension is not approved and no deal closes by March 28, 2026, the company will redeem all public shares and liquidate the SPAC. Public holders may redeem their shares in connection with the extension vote for cash equal to their portion of the trust.
As of the February 11, 2026 record date, there were 5,739,970 common shares outstanding and approximately $16.092 million in the trust account, implying an estimated redemption price of about $10.76 per share at the special meeting. Sponsor‑related holders own about 63% of the outstanding shares and favor the extension, but public redemptions could significantly reduce trust cash and may affect Nasdaq listing status.
AQR Capital Management, LLC and its affiliates report a significant passive stake in IB Acquisition Corp. The AQR entities collectively beneficially own 688,646 shares of IB Acquisition Corp. common stock, representing 12% of the class. They report zero sole voting or dispositive power and shared voting and dispositive power over all 688,646 shares.
The filing is a Schedule 13G/A, indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC is deemed controlled by AQR Capital Management, LLC.
IB Acquisition Corp. received an amended ownership report from Bank of Montreal and related entities. In this Schedule 13G/A (Amendment No. 1), Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. each report beneficial ownership of 0 common shares, representing 0% of the class.
They state no sole or shared power to vote or dispose of any IB Acquisition Corp. shares and certify that any securities referred to were acquired and held in the ordinary course of business, not to change or influence control of the company.
IB Acquisition Corp, a blank check company, reported a net loss of $58,902 for the quarter ended December 31, 2025, compared with net income of $907,068 a year earlier. Interest and dividends on the trust account fell to $153,289 from $1,371,530, while general and administrative expenses were $180,000.
The company held $16,043,483 in its trust account and cash of $165,484 outside the trust, with a working capital deficit of $800,393. After $106.1M of redemptions in September 2025, 1,490,880 shares remain redeemable. Management discloses substantial doubt about its ability to continue as a going concern if a business combination is not completed by March 28, 2026.
Barclays PLC filed an amended Schedule 13G showing beneficial ownership of 20,000 shares of IB Acquisition Corp common stock, representing 0.34% of the class as of 12/31/2025. Barclays reports sole voting and dispositive power over all 20,000 shares.
The filing states these securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of IB Acquisition Corp or in connection with any control-related transaction.